Indium Dtpa (In111) Curium Netherlands (Indium (111in) Pentetate)

• Indium-111 DTPA is employed in diagnostic imaging of cerebrospinal fluid pathways.
• Cerebrospinal fluid flow studies: assesses CSF circulation and identifies blockages.
• Detection of CSF leaks: localizes sites of spinal or cranial cerebrospinal fluid leakage.
• Post‑operative CSF assessment: evaluates CSF dynamics after neurosurgical procedures.

• Indium-111 is chelated by diethylenetriamine pentaacetic acid (DTPA) to form a stable complex that, when administered intrathecally, distributes within the cerebrospinal fluid. The indium‑111 isotope emits gamma photons that are detected by a gamma camera, allowing high‑resolution visualization of CSF pathways and potential leaks.

Adverse reactions may occur following intrathecal administration of Indium-111 DTPA.

Common Side Effects

• Headache: mild to moderate discomfort after lumbar puncture.
• Nausea: transient feeling of queasiness.
• Back pain: mild soreness at puncture site.
• Transient fever: low‑grade temperature rise.
• Lumbar puncture site discomfort: localized irritation.
• Mild hypotension: temporary blood pressure drop.

Serious or Rare Side Effects

• Allergic reaction or anaphylaxis: severe hypersensitivity requiring immediate care.
• Severe meningitis: infection of the central nervous system.
• Radiation‑induced myelopathy: rare spinal cord injury from radiation exposure.
• CSF infection: bacterial contamination of the intrathecal space.
• Severe neurological deficit: unexpected loss of function following injection.

• Proper handling and patient monitoring are essential when using this radiopharmaceutical.
• Verify radiolabeling integrity: confirm correct activity before administration.
• Maintain sterile technique: use aseptic procedures for intrathecal injection.
• Assess patient allergy history: screen for hypersensitivity to DTPA or indium.
• Monitor vital signs post‑procedure: observe for hemodynamic changes.
• Implement radiation safety measures: protect staff and environment from exposure.
• Store at ambient temperature: keep in original shielded container, protect from light and moisture.

Indium-111 DTPA may interact with other agents that affect imaging quality or patient safety.

Major Interactions (Avoid)

• Concurrent radiopharmaceuticals with overlapping gamma emissions: may obscure imaging results.
• High‑dose iodine contrast agents: can interfere with gamma detection.
• Strong chelating agents (e.g., EDTA): may strip indium from DTPA.

Moderate Interactions (Monitor Closely)

• Anticoagulants: increase risk of bleeding from lumbar puncture.
• CNS depressants: may mask neurologic symptoms.
• Immunosuppressants: elevate infection risk after intrathecal administration.